Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CE-224535 (PF-04905428) is a selective antagonist of P2X7 receptor. CE-224535 can be used in disease-modifying antirheumatic studies.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 213.00 | |
5 mg | In stock | $ 537.00 | |
10 mg | In stock | $ 775.00 | |
25 mg | In stock | $ 1,190.00 | |
50 mg | In stock | $ 1,590.00 | |
100 mg | In stock | $ 2,170.00 | |
500 mg | In stock | $ 4,350.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 413.00 |
Description | CE-224535 (PF-04905428) is a selective antagonist of P2X7 receptor. CE-224535 can be used in disease-modifying antirheumatic studies. |
In vitro | CE-224535 reduces leukocyte secretion of IL-1 and IL-18, thereby providing a novel therapeutic approach for the treatment of rheumatoid arthritis[1]. |
In vivo | In rats, CE-224535 has low CLp (11 mL/min/kg) and a large Vdss of 7.6 L/kg, which results in a half-life of 2.4 h. CE-224535 (5 mg/kg;oral) provides Cmax that is ~90 fold over its IC90 in human blood (0.21 μg/mL or 0.44 μM)[2]. |
Synonyms | PF-04905428 |
Molecular Weight | 480.94 |
Formula | C22H29ClN4O6 |
CAS No. | 724424-43-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95 mg/mL (197.53 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CE-224535 724424-43-5 Membrane transporter/Ion channel Neuroscience P2X Receptor inhibit PF-04905428 P2XRs Inhibitor PF04905428 PF 04905428 CE 224535 CE224535 inhibitor